TITLE

Twice-daily insulin regimens in management of severe diabetes

AUTHOR(S)
Oakley, Nigel; Mather, Hugh; Hadley, Lindsay; Lynch, Janice; Pilkington, Thomas
PUB. DATE
May 1981
SOURCE
Journal of the Royal Society of Medicine;May1981, Vol. 74 Issue 5, p363
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Diurnal glucose profiles have been compared in ten insulin dependent diabetics receiving, firstly, a twice-daily soluble insulin (SI): isophane insulin (NPHI) regimen containing a high proportion of SI (mean 73%O) and, secondly, Mixtard insulin (30% SI, 70% NPHI). For each patient the two regimens gave similar profiles though nocturnal blood glucose control was better on Mixtard. HbA1 values were similar on the two regimens. The findings show that, using highly purified formulations, small changes in insulin proportions in twice-daily SI: NPHI regimens may be irrelevant to diabetic control; they also suggest that highly purified NPHI may have a substantially shorter duration of action than its older counterpart and that the convenient regimen of twice-daily Mixtard is usually as good as any more complicated ‘tailormade’ regimen of highly purified insulins.
ACCESSION #
22758997

 

Related Articles

  • Converting people with type 2 diabetes to insulin. Rodgers, Jill // British Journal of Community Nursing;Nov2004, Vol. 9 Issue 11, p495 

    Type 2 diabetes has commonly been viewed as more benign than type 1, partly because it was once rare to use insulin in its management. With the recognition of the importance of tight control of blood glucose, it is now the case that most people with type 2 diabetes will require insulin at some...

  • Baseline A1C Level Is the Key.  // Diabetes Health;Jan2005, Vol. 14 Issue 1, p65 

    Presents information on the results of a study conducted by researchers from the University of Toronto on the effectivity of rapid-acting insulin analogs Novolog and Humalog compared to multiple daily insulin injections (MDII) in achieving optimal blood glucose control in people with higher A1C...

  • Chronic glucose-lowering effects of rosiglitazone and bis(ethylmaltolato)oxovanadium(IV) in ZDF rats. Yuen, Violet G.; Bhanot, Sanjay; Battell, Mary L.; Orvig, Chris; McNeill, John H. // Canadian Journal of Physiology & Pharmacology;Nov2003, Vol. 81 Issue 11, p1049 

    The aim of this study was to determine if there was a synergistic or additive effect of a thiazolidinedione derivative (rosiglitazone (ROS)) and a vanadium compound (bis(ethylmaltolato)oxovanadium(IV) (BEOV)) on plasma glucose and insulin levels following chronic oral administration to Zucker...

  • The hypoglycemic activity of Coccinia indica Wight & Arn. and its influence on certain biochemical parameters. Dhanabal, S. P.; Koate, C. K.; Ramanathan, M.; Elango, K.; Suresh, B. // Indian Journal of Pharmacology;Aug2004, Vol. 36 Issue 4, p249 

    Coccinia indica, which is grown abundantly in India have been widely used in the traditional treatment of diabetes mellitus. Researchers reported hypoglycemic action of the pectin isolated from the fruit of Coccinia indica. Contradictory findings on the antidiabetic activity of the different...

  • Fact or romour.  // Prevention India;Sep2010, p3 

    The article focuses on whether eating sugar causes diabetes. It tells that eating sugar does not cause diabetes but it is important for diabetic patients to control the amount of sugar they eat. It informs that diabetes is a mismatch between sugar in the bloodstream and the action of insulin. It...

  • Cdk5-dependent regulation of glucose-stimulated insulin secretion. Fan-Yan Wei; Nagashima, Kazuaki; Ohshima, Toshio; Saheki, Yasunori; Yun-Fei Lu; Matsushita, Masayuki; Yamada, Yuichiro; Mikoshiba, Katsuhiko; Seino, Yutaka; Matsui, Hideki; Tomizawa, Kazuhito // Nature Medicine;Oct2005, Vol. 11 Issue 10, p1104 

    Tight glycemic control in individuals with diabetes mellitus is essential to prevent or delay its complications. Present treatments to reduce hyperglycemia mainly target the ATP-sensitive K+ (KATP) channel of pancreatic beta cells to increase insulin secretion. These current approaches are often...

  • Hypoglycemia. Fowler, Michael J. // Clinical Diabetes;Fall2008, Vol. 26 Issue 4, p170 

    The article discusses the fundamentals of diabetes management, focusing on hypoglycemia as a potential complication to diabetes treatment. It mentions that intensive treatment of diabetes brings the risk of lowering blood glucose levels excessively and causing hypoglycemia. The use of exogenous...

  • Metformin Improved Glycemic Control in Patients with Type 1 Diabetes. Gottlieb, Peter A.; Ellis, Samuel L.; Lopez, Phillip; Gutin, Raymond; Garg, Satish K. // Diabetes;Jun2007 Supplement 1, Vol. 56, pA574 

    The purpose of this study was to evaluate glycemic control in adult patients with type 1 diabetes prescribed to metformin therapy from January 2000 to December 2005. Secondary outcomes included weight, BMI, and insulin dose. This was a retrospective study with a computer matched control group in...

  • Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Heise, Tim; Nosek, Leszek; Rønn, Birgitte Biilmann; Endahl, Lars; Heinemann, Lutz; Kapitza, Christoph; Draeger, Eberhard; Rønn, Birgitte Biilmann // Diabetes;Jun2004, Vol. 53 Issue 6, p1614 

    The aim of this randomized double-blind study was to compare the within-subject variability of the glucose-lowering effect of a novel insulin analog, insulin detemir, with that of insulin glargine and NPH insulin in people with type 1 diabetes. Fifty-four subjects (32 males and 22 females, age...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics